Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation.

Hicks MJ, Rosenberg JB, De BP, Pagovich OE, Young CN, Qiu JP, Kaminsky SM, Hackett NR, Worgall S, Janda KD, Davisson RL, Crystal RG.

Sci Transl Med. 2012 Jun 27;4(140):140ra87. doi: 10.1126/scitranslmed.3003611.

2.

AAVrh.10-mediated expression of an anti-cocaine antibody mediates persistent passive immunization that suppresses cocaine-induced behavior.

Rosenberg JB, Hicks MJ, De BP, Pagovich O, Frenk E, Janda KD, Wee S, Koob GF, Hackett NR, Kaminsky SM, Worgall S, Tignor N, Mezey JG, Crystal RG.

Hum Gene Ther. 2012 May;23(5):451-9. doi: 10.1089/hum.2011.178.

3.

Genetic delivery of an anti-RSV antibody to protect against pulmonary infection with RSV.

Skaricic D, Traube C, De B, Joh J, Boyer J, Crystal RG, Worgall S.

Virology. 2008 Aug 15;378(1):79-85. doi: 10.1016/j.virol.2008.04.016. Epub 2008 Jun 16.

4.

Combined active and passive immunization against nicotine: minimizing monoclonal antibody requirements using a target antibody concentration strategy.

Cornish KE, Harris AC, LeSage MG, Keyler DE, Burroughs D, Earley C, Pentel PR.

Int Immunopharmacol. 2011 Nov;11(11):1809-15. doi: 10.1016/j.intimp.2011.07.009. Epub 2011 Jul 28.

5.

Therapeutic vaccines for nicotine dependence.

Maurer P, Bachmann MF.

Curr Opin Mol Ther. 2006 Feb;8(1):11-6. Review.

PMID:
16506520
6.

High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses.

De BP, Heguy A, Hackett NR, Ferris B, Leopold PL, Lee J, Pierre L, Gao G, Wilson JM, Crystal RG.

Mol Ther. 2006 Jan;13(1):67-76. Epub 2005 Nov 2.

7.

Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine.

Rosenberg JB, De BP, Hicks MJ, Janda KD, Kaminsky SM, Worgall S, Crystal RG.

Hum Gene Ther. 2013 Jun;24(6):595-603. doi: 10.1089/hum.2012.245.

8.

Enhancing immunogenicity of a 3'aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates.

McCluskie MJ, Pryde DC, Gervais DP, Stead DR, Zhang N, Benoit M, Robertson K, Kim IJ, Tharmanathan T, Merson JR, Davis HL.

Int Immunopharmacol. 2013 May;16(1):50-6. doi: 10.1016/j.intimp.2013.03.021. Epub 2013 Apr 2.

PMID:
23562759
9.

Novel Anti-Nicotine Vaccine Using a Trimeric Coiled-Coil Hapten Carrier.

Miller KD, Roque R, Clegg CH.

PLoS One. 2014 Dec 10;9(12):e114366. doi: 10.1371/journal.pone.0114366. eCollection 2014.

10.

New directions in nicotine vaccine design and use.

Pentel PR, LeSage MG.

Adv Pharmacol. 2014;69:553-80. doi: 10.1016/B978-0-12-420118-7.00014-7. Review.

11.

Probing the protective effects of a conformationally constrained nicotine vaccine.

Moreno AY, Azar MR, Koob GF, Janda KD.

Vaccine. 2012 Oct 19;30(47):6665-70. doi: 10.1016/j.vaccine.2012.08.064. Epub 2012 Sep 7.

PMID:
22963803
12.

Growth inhibition of an established A431 xenograft tumor by a full-length anti-EGFR antibody following gene delivery by AAV.

Ho DT, Wykoff-Clary S, Gross CS, Schneider D, Jin F, Kretschmer PJ, Hermiston TW.

Cancer Gene Ther. 2009 Feb;16(2):184-94. doi: 10.1038/cgt.2008.68. Epub 2008 Aug 29.

PMID:
18758433
13.

Differential effects of passive immunization with nicotine-specific antibodies on the acute and chronic distribution of nicotine to brain in rats.

Pentel PR, Dufek MB, Roiko SA, Lesage MG, Keyler DE.

J Pharmacol Exp Ther. 2006 May;317(2):660-6. Epub 2006 Jan 11.

PMID:
16407464
14.

Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential.

Li Q, Miller R, Han PY, Pang J, Dinculescu A, Chiodo V, Hauswirth WW.

Mol Vis. 2008 Sep 24;14:1760-9.

15.

[Smoking reduction and temporary abstinence: new approaches for smoking cessation].

Le Houezec J, Säwe U.

J Mal Vasc. 2003 Dec;28(5):293-300. Review. French.

PMID:
14978435
17.

Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab.

Muthumani K, Flingai S, Wise M, Tingey C, Ugen KE, Weiner DB.

Hum Vaccin Immunother. 2013 Oct;9(10):2253-62. doi: 10.4161/hv.26498. Epub 2013 Sep 17.

18.

Nicotine vaccines to assist with smoking cessation: current status of research.

Raupach T, Hoogsteder PH, Onno van Schayck CP.

Drugs. 2012 Mar 5;72(4):e1-16. doi: 10.2165/11599900-000000000-00000. Review.

19.

Adeno-associated virus-mediated anti-DR5 chimeric antibody expression suppresses human tumor growth in nude mice.

Lv F, Qiu Y, Zhang Y, Liu S, Shi J, Liu Y, Zheng D.

Cancer Lett. 2011 Mar 28;302(2):119-27. doi: 10.1016/j.canlet.2011.01.001.

PMID:
21306822
20.

Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody.

Tars K, Kotelovica S, Lipowsky G, Bauer M, Beerli RR, Bachmann MF, Maurer P.

J Mol Biol. 2012 Jan 6;415(1):118-27. doi: 10.1016/j.jmb.2011.10.042. Epub 2011 Nov 3.

PMID:
22079050

Supplemental Content

Support Center